The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A08 | Antiobesity preparations, excl. diet products | |
| 3 | A08A | Antiobesity preparations, excl. diet products | |
| 4 | A08AB | Peripherally acting antiobesity products | |
| 5 | A08AB01 | Orlistat |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.36 g |
| Active Ingredient | Description | |
|---|---|---|
| Orlistat |
Orlistat is a potent, specific and long-acting inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of the gastric and pancreatic lipases. The inactivated enzyme is thus unavailable to hydrolyse dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| XENICAL Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| XENICAL Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
